Abstract:T he ability of grapefruit juice to increase drug levels in blood was accidentally discovered during a pharmacokinetic study designed to evaluate an interaction between felodipine (Plendil), a drug prescribed for treatment of hypertension, and ethanol. Double-strength grapefruit juice was used to mask the taste of the ethanol in this randomized, crossover, double-blind study. A nonintoxicating dose of ethanol or placebo was administered to subjects, followed by a 5-mg dose of felodipine. For both study arms, serum felodipine concentrations were noted to be several times greater than that previously reported at that same dose when grapefruit juice was not used. It was then recognized that this finding was possibly due to a pharmacodynamic interaction between grapefruit juice and felodipine. Since this observation, much research has focused on the mechanisms of drugYgrapefruit juice interactions and the medications that interact with the juice. Grapefruit juice is very popular, purchased by 21% of all households in the United States. The United States produces nearly 40% of the world’s supply of grapefruit, with Florida being the largest producer, averaging 2 million tons of fruit per year. Grapefruit is endorsed by the American Heart Association as a ‘‘heart-healthy food’’ because it contains compounds that may reduce the formation of artherosclerotic plaques. It may also inhibit cancer cell proliferation. The compounds in grapefruit juice, however, may also be responsible for clinically significant drug interactions with numerous prescription medications, thus raising potential concern regarding whether it should be consumed at the same time with them. Its effects are most pronounced on cyclosporine, some calcium antagonists, and the hydroxymethylglutarylYcoenzyme A reductase inhibitors. In oral doses of approximately 8 oz, grapefruit juice increases the serum concentrations of these drugs from 1.5to 15-fold. For some drugs such as felodipine and nicardipine, the increased drug concentrations could potentially be associated with an increased frequency of dose-dependent adverse effects, although actual reports of toxicity with drugYgrapefruit juice interactions have been rare. The drugYgrapefruit juice interaction is caused by inhibition of the intestinal cytochrome P-450 enzyme system, particularly cytochrome P450 3A4 (CYP450 3A4), by 1 or more of the components in grapefruit juice. Many active components in grapefruit juice have been evaluated for potentially causing this interaction, including flavonoids such as naringenin, naringin, quercetin, and kaempferol, and nonflavonoids such as 6,7-dihydroxybergamottin, bergaptol, and 6,7-epoxybergamottin. Naringin, the glycoside of naringenin, is the most abundant flavonoid in grapefruit juice, constituting up to 10% of its dry weight. Naringin is not found in other citrus or fruit juices and is responsible for the distinctive smell and bitter taste of grapefruit juice. Naringin exerts no effect on the activity of the CYP450 system in vitro, but in vivo, its metabolite, naringenin, is a potent inhibitor of both the CYP 3A and CYP 1A2 isoforms. However, most research suggests the furanocoumarin 6,7-didydroxybergamottin and/or its parent compound bergamottin to be the major CYP 3A4 inhibitors found in grapefruit juice.

Interactions between grapefruit juice and psychotropic medications: an update of the literature and an original case series

Food-drug Interactions Precipitated by Fruit Juices Other Than Grapefruit Juice: an Update Review

Physiologically Based Pharmacokinetic Modeling of Bergamottin and 6,7-Dihydroxybergamottin to Describe CYP3A4 Mediated Grapefruit-Drug Interactions

Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance

Analysis of prescriptions of three selective serotonin reuptake inhibitors from a perspective of metabolic interactions

Rational Prescription of Drugs Within Similar Therapeutic or Structural Class for Gastrointestinal Disease Treatment： Drug Metabolism and Its Related Interactions

Dose-response relationship for the pharmacokinetic interaction of grapefruit juice with dextromethorphan investigated by human urinary metabolite profiles

Impact of Pomegranate Juice on the Pharmacokinetics of CYP3A4- and CYP2C9-Mediated Drugs Metabolism: A Preclinical and Clinical Review

Food–Drug Interactions with Fruit Juices

Interaction Between Grapefruit Juice and Hypnotic Drugs: Comparison of Triazolam and Quazepam

Clinically Significant Grapefruit Juice-Drug Interactions

Effect of grapefruit juice and food on the pharmacokinetics of pirfenidone in healthy Chinese volunteers: a diet–drug interaction study

Update of green tea interactions with cardiovascular drugs and putative mechanisms

Selective Serotonin Reuptake Inhibitors and Cytochrome P-450 Mediated Drug-Drug Interactions: An Update

In vitro interactions with repeated grapefruit juice administration--to peel or not to peel?

The Effect of Grapefruit Juice on Clinical Drug

Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans

A Narrative Review on Pharmacogenomics in Psychiatry: Scientific Definitions, Principles, and Practical Resources

Effects of Ginkgo biloba extract on CYP and drug interactions with other drugs

Influence of CYP3A5 and MDR1 Genetic Polymorphisms on Urinary 6β‐hydroxycortisol/cortisol Ratio after Grapefruit Juice Intake in Healthy Chinese

Prioritizing pharmacokinetic drug interaction precipitants in natural products: application to OATP inhibitors in grapefruit juice